NCT07169318 - First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions

Influenza

Interventions

OTHER

Placebo for VNT-101

Capsules will be size 00 and filled with microcrystalline cellulose

DRUG

VNT-101

VNT-101 is an orally bioavailable, direct-acting antiviral with a novel mechanism of action - inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.

Trial Locations (1)

66212

RECRUITING

Altasciences Inc - Kansas City, Overland Park

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH